ABSTRACT
Early diagnosis of COVID-19 is considered the first key action to prevent spread of the virus. Currently, reverse transcription-polymerase chain reaction (RT-PCR) is considered as a gold standard point-of-care diagnostic tool. However, several limitations of RT-PCR have been identified, e.g., low sensitivity, cost, long delay in getting results and the need of a professional technician to collect samples. On the other hand, chest X-ray (CXR) is routinely used as a cost-effective diagnostic test for diagnosis and monitoring different respiratory abnormalities and is currently being used as a discriminating tool for COVID-19. However, visual assessment of CXR is not able to distinguish COVID-19 from other lung conditions. Several machine learning algorithms have been proposed to detect COVID-19 directly from CXR images with reasonably good accuracy on a data set that was randomly split into two subsets for training and test. Since these methods require a huge number of images for training, data augmentation with geometric transformation was applied to increase the number of images. It is highly likely that the images of the same patients are present in both the training and test sets resulting in higher accuracies in detection of COVID-19. It is, therefore, vital to assess the performance of COVID-19 detection algorithm on an independent data set with different degrees of the disease before being employed for clinical settings. On the other hand, machine learning techniques that depend on handcrafted features extraction and selection approaches can be trained with smaller data set. The features can also be analyzed separately for various lung conditions. Radiomics features are such kind of handcrafted features that represent heterogeneous appearance of the lung on CXR quantitatively and can be used to distinguish COVID-19 from other lung conditions. Based on this hypothesis, a machine learning based technique is proposed here that is trained on a set of suitable radiomics features (71 features) to detect COVID-19. It is found that Support Vector Machine (SVM) and Ensemble Bagging Model Trees (EBM) trained on these 71 radiomics features can distinguish between COVID-19 and other diseases with an overall sensitivity of 99.6% and 87.8% and specificity of 85% and 97% respectively. Though the performance is comparable for both methods, EBM is more robust across severity levels. Severity, in this case, was scored between 0 to 4 by two experienced radiologists for each lung segment of each CXR image represents the degree of severity of the disease. For the case of 0 severity, sensitivity and specificity of the EBM method are 91.7% and 100% respectively indicating that there are certain radiomics pattern that are not visibly distinguishable. Since the proposed method does not require any manual intervention (e.g., sample collection etc.), it can be integrated with any standard X-ray reporting system to be used as an efficient, cost-effective and rapid early diagnosis device. It can also be deployed in places where quick results of the COVID-19 test are required, e.g., airports, seaports, hospitals, health clinics, etc.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors extend appreciation to the Deputyship for Research & Innovation, Ministry of Saudi Arabia for funding this research work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB waived as it was a retrospective study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data related to the findings of this study are available from the authors on reasonable request.